Show simple item record

dc.contributor.authorWorld Health Organization, Regional Office for the Eastern Mediterranean
dc.date.accessioned2014-06-17T12:29:57Z
dc.date.available2014-06-17T12:29:57Z
dc.date.issued2009EN
dc.identifier.isbn978-92-9021-652-0EN
dc.identifier.otherhttp://applications.emro.who.int/dsaf/dsa1003.pdfEN
dc.identifier.urihttps://apps.who.int/iris/handle/10665/119889
dc.description98 p. ; 30 cm.EN
dc.description.abstractThis report presents the finding of the first phase of the national Good Governance for Medicines programme in the Syrian Arab Republic. In recent years, countries of the WHO Eastern Mediterranean Region have made significant achievements in the provision of health services. In the pharmaceutical field, countries have been striving to improve the structures and regulations pertaining to medicines and have progressed in many ways. However, there are still important challenges. The goal of the WHO Good Governance for Medicines programme is to improve the situation of medicines regulation and supply. National transparency assessment is the beginning of a process aimed at bringing about desirable and sustainable changes in the governance of the pharmaceutical sectorEN
dc.language.isoenEN
dc.subjectPharmaceutical ServicesEN
dc.subjectPublic SectorEN
dc.subjectDrug ApprovalEN
dc.subjectDrug EvaluationEN
dc.subject.meshPharmacologyEN
dc.subject.meshعلم الأدويةEN
dc.titleMeasuring transparency to improve good governance in the public pharmaceutical sector: Syrian Arab RepublicEN
dc.title.alternativeقياس الشفافية لتحسين الادارة الرشيدة [‎الشوروية]‎ فى القطاع العام للادوية. الجمهورية العربية السوريةEN


Files in this item

Thumbnail

This item appears in the following Collection(‎s)‎

Show simple item record